Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors

Abstract Background PD-L1 immunohistochemistry (IHC) has been traditionally used for predicting clinical responses to immune checkpoint inhibitors (ICIs). However, there are at least 4 different assays and antibodies used for PD-L1 IHC, each developed with a different ICI. We set to test if next gen...

Full description

Bibliographic Details
Main Authors: Jeffrey M. Conroy, Sarabjot Pabla, Mary K. Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, Blake Burgher, Jonathan Andreas, Vincent Giamo, Yirong Wang, Felicia L. Lenzo, Wiam Bshara, Maya Khalil, Grace K. Dy, Katherine G. Madden, Keisuke Shirai, Konstantin Dragnev, Laura J. Tafe, Jason Zhu, Matthew Labriola, Daniele Marin, Shannon J. McCall, Jeffrey Clarke, Daniel J. George, Tian Zhang, Matthew Zibelman, Pooja Ghatalia, Isabel Araujo-Fernandez, Luis de la Cruz-Merino, Arun Singavi, Ben George, Alexander C. MacKinnon, Jonathan Thompson, Rajbir Singh, Robin Jacob, Deepa Kasuganti, Neel Shah, Roger Day, Lorenzo Galluzzi, Mark Gardner, Carl Morrison
Format: Article
Language:English
Published: BMJ Publishing Group 2019-01-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Atezolizumab
Avelumab
cancer immunotherapy
Durvalumab
Nivolumab
Pembrolizumab
Online Access:http://link.springer.com/article/10.1186/s40425-018-0489-5

Internet

http://link.springer.com/article/10.1186/s40425-018-0489-5

Similar Items